Nuclasta 60mg injection contains denosumab, a monoclonal antibody medicine used to treat osteoporosis in postmenopausal women and in men at increased risk of fractures. It helps slow bone loss, strengthen bones, and reduce the risk of spine, hip, and other fractures by blocking a protein involved in bone breakdown. Your doctor will decide if this treatment is suitable for your condition.

Nuclasta 60mg injection is administered as a subcutaneous injection by a qualified healthcare professional. Do not self-administer this medicine. It is usually given once every six months or as prescribed by your doctor. The injection may be administered in the upper arm, thigh, or abdomen. To enhance effectiveness, your doctor may recommend taking adequate calcium and vitamin D during treatment.

Common side effects may include musculoskeletal pain such as bone, joint, or muscle pain, pain in the arms or legs, headache, rash, nerve pain, constipation, and urinary tract infections. Some people may also experience upper respiratory tract symptoms and abdominal discomfort. Rare but serious side effects can include low blood calcium levels, osteonecrosis of the jaw, and atypical fractures. Contact your doctor immediately if you experience severe or unusual symptoms such as sudden jaw pain or significant bone or joint pain.

Nuclasta 60mg injection is available from authorised pharmacies or speciality medicine suppliers with a valid prescription. Contact Macarius Health to check availability and pricing in your area.

Store Nuclasta 60mg injection in a refrigerator between 2°C and 8°C. Do not freeze. Keep the injection in its original packaging to protect it from light and moisture, and keep it out of reach of children and pets. If removed from the refrigerator, follow your healthcare provider’s guidance on how long it may be kept at room temperature before use.

Inform your doctor about all medicines, supplements, or herbal products you are taking. Some medicines, especially those affecting calcium levels or bone metabolism, may interact with denosumab and increase the risk of side effects or affect treatment effectiveness. Your doctor may adjust treatment or monitoring if required.

Nuclasta 60mg injection is not recommended during pregnancy due to potential harm to an unborn baby. Effective contraception is usually advised during treatment and for a period after the last dose if you can become pregnant. Denosumab may also pass into breast milk and could pose a risk to a nursing infant. Discuss risks, benefits, and contraception requirements with your healthcare provider before starting treatment.

Delivery time depends on stock availability and location. Macarius Health arranges prompt delivery within Delhi NCR. For other cities across India, delivery typically follows standard courier timelines.